Enorama Pharma AB (publ) (ERMA.ST)
SEK 2.13
(-4.05%)
SEK 2.13
(-4.05%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 4.29 Million SEK | 51.29% |
| 2022 | 2.83 Million SEK | 129.16% |
| 2021 | 1.23 Million SEK | -27.9% |
| 2020 | 1.71 Million SEK | 171699900.0% |
| 2019 | 1.00 SEK | 100.0% |
| 2018 | -1.1 Million SEK | 30.46% |
| 2017 | -1.59 Million SEK | -1826.1% |
| 2016 | -82.84 Thousand SEK | 66.83% |
| 2015 | -249.73 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 8.14 Million SEK | -3.23% |
| 2024 Q1 | 8.41 Million SEK | 96.06% |
| 2023 FY | 4.29 Million SEK | 51.29% |
| 2023 Q3 | 5.63 Million SEK | 17.7% |
| 2023 Q4 | 4.29 Million SEK | -23.79% |
| 2023 Q2 | 4.78 Million SEK | 4.59% |
| 2023 Q1 | 4.57 Million SEK | 61.26% |
| 2022 FY | 2.83 Million SEK | 129.16% |
| 2022 Q4 | 2.83 Million SEK | 4.76% |
| 2022 Q3 | 2.7 Million SEK | 1.73% |
| 2022 Q2 | 2.66 Million SEK | 56.96% |
| 2022 Q1 | 1.69 Million SEK | 37.0% |
| 2021 Q2 | 2.11 Million SEK | 23.38% |
| 2021 Q1 | 1.71 Million SEK | -0.12% |
| 2021 Q4 | 1.23 Million SEK | -31.75% |
| 2021 Q3 | 1.81 Million SEK | -14.27% |
| 2021 FY | 1.23 Million SEK | -27.9% |
| 2020 Q1 | 956 Thousand SEK | 95599900.0% |
| 2020 Q4 | 1.71 Million SEK | 1.6% |
| 2020 Q3 | 1.69 Million SEK | 70.71% |
| 2020 Q2 | 990 Thousand SEK | 3.56% |
| 2020 FY | 1.71 Million SEK | 171699900.0% |
| 2019 Q4 | 1.00 SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | -100.0% |
| 2019 Q1 | 1.00 SEK | 0.0% |
| 2019 FY | 1.00 SEK | 100.0% |
| 2018 Q3 | - SEK | -100.0% |
| 2018 Q2 | 1.00 SEK | 0.0% |
| 2018 FY | -1.1 Million SEK | 30.46% |
| 2018 Q4 | 1.00 SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 FY | -1.59 Million SEK | -1826.1% |
| 2017 Q3 | - SEK | 0.0% |
| 2016 FY | -82.84 Thousand SEK | 66.83% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | -249.73 Thousand SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AcuCort AB | -1.09 Million SEK | 490.537% |
| AlzeCure Pharma AB (publ) | -2508.00 SEK | 171232.376% |
| BioGaia AB (publ) | 181.2 Million SEK | 97.631% |
| Enzymatica AB (publ) | 11.49 Million SEK | 62.675% |
| Gabather AB (publ) | -1772.00 SEK | 242312.19% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 7.11 Million SEK | 39.677% |
| Nanexa AB (publ) | 1.91 Million SEK | -124.594% |
| Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | 14.074% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 42.4 Million SEK | 89.877% |
| Probi AB (publ) | 116.7 Million SEK | 96.322% |
| Swedencare AB (publ) | 398.1 Million SEK | 98.922% |
| Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 99.889% |
| Toleranzia AB | -1.34 Million SEK | 420.299% |
| Vivesto AB | - SEK | -Infinity% |